JPWO2019204564A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019204564A5 JPWO2019204564A5 JP2020556851A JP2020556851A JPWO2019204564A5 JP WO2019204564 A5 JPWO2019204564 A5 JP WO2019204564A5 JP 2020556851 A JP2020556851 A JP 2020556851A JP 2020556851 A JP2020556851 A JP 2020556851A JP WO2019204564 A5 JPWO2019204564 A5 JP WO2019204564A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- domain
- ror
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 432
- 102000036639 antigens Human genes 0.000 claims description 432
- 108091007433 antigens Proteins 0.000 claims description 432
- 102000005962 receptors Human genes 0.000 claims description 258
- 108020003175 receptors Proteins 0.000 claims description 258
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 176
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 44
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 22
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 22
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 22
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 11
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 8
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 8
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000027257 transmembrane receptors Human genes 0.000 claims description 8
- 108091008578 transmembrane receptors Proteins 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000000375 direct analysis in real time Methods 0.000 claims description 2
- 238000012063 dual-affinity re-targeting Methods 0.000 claims description 2
- 238000009261 endocrine therapy Methods 0.000 claims description 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 102220269348 rs61747367 Human genes 0.000 claims 3
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 description 70
- 230000003993 interaction Effects 0.000 description 68
- 229920001184 polypeptide Polymers 0.000 description 56
- 102000004196 processed proteins & peptides Human genes 0.000 description 56
- 108090000765 processed proteins & peptides Proteins 0.000 description 56
- 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 description 30
- 101710119577 Molybdopterin molybdenumtransferase Proteins 0.000 description 30
- 238000012986 modification Methods 0.000 description 29
- 230000004048 modification Effects 0.000 description 29
- 238000000034 method Methods 0.000 description 15
- 210000004899 c-terminal region Anatomy 0.000 description 14
- 102100021651 SUN domain-containing ossification factor Human genes 0.000 description 9
- 102220504584 Beta-ureidopropionase_D54E_mutation Human genes 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023172867A JP2023168551A (ja) | 2018-04-18 | 2023-10-04 | 抗ｒｏｒ抗体構築物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659635P | 2018-04-18 | 2018-04-18 | |
| US62/659,635 | 2018-04-18 | ||
| PCT/US2019/028051 WO2019204564A1 (en) | 2018-04-18 | 2019-04-18 | Anti-ror antibody constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172867A Division JP2023168551A (ja) | 2018-04-18 | 2023-10-04 | 抗ｒｏｒ抗体構築物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522162A JP2021522162A (ja) | 2021-08-30 |
| JPWO2019204564A5 true JPWO2019204564A5 (enrdf_load_stackoverflow) | 2022-04-25 |
Family
ID=68239890
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556851A Pending JP2021522162A (ja) | 2018-04-18 | 2019-04-18 | 抗ｒｏｒ抗体構築物 |
| JP2023172867A Withdrawn JP2023168551A (ja) | 2018-04-18 | 2023-10-04 | 抗ｒｏｒ抗体構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172867A Withdrawn JP2023168551A (ja) | 2018-04-18 | 2023-10-04 | 抗ｒｏｒ抗体構築物 |
Country Status (15)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ752832A (en) * | 2016-10-19 | 2025-06-27 | Invenra Inc | Antibody constructs |
| US20240010753A1 (en) * | 2020-08-24 | 2024-01-11 | Epimab Biotherapeutics (Hk) Limited | Anti-ror1 antibodies and related bispecific binding proteins |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| KR20240043784A (ko) * | 2021-08-09 | 2024-04-03 | 메르크 파텐트 게엠베하 | 염증유발성 시토카인의 방출로부터 t 세포-매개 종양 세포독성을 디커플링시키는 단백질 |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2023178257A1 (en) * | 2022-03-18 | 2023-09-21 | Novascope Biochips Inc. | Antibody for porcine reproductive and respiratory syndrome virus and uses thereof |
| US12144869B2 (en) * | 2022-06-30 | 2024-11-19 | Sutro Biopharma, Inc. | Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates |
| WO2024207177A1 (en) * | 2023-04-04 | 2024-10-10 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
| KR20240016216A (ko) * | 2022-07-26 | 2024-02-06 | (주)에임드바이오 | 항-ror1 항체 및 이의 용도 |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| GB202216284D0 (en) * | 2022-11-02 | 2022-12-14 | Ucl Business Ltd | Self-regulation |
| AU2023409023A1 (en) * | 2022-12-20 | 2025-07-31 | Oncternal Therapeutics, Inc. | Combination therapies for the treatment of cancer |
| TW202517683A (zh) * | 2023-07-20 | 2025-05-01 | 美商艾克塞里克斯公司 | 可活化之ror結合劑及其用途 |
| TW202517681A (zh) * | 2023-07-20 | 2025-05-01 | 美商艾克塞里克斯公司 | 酪胺酸-蛋白質激酶膜受體1 (ror1)抗體-藥物結合物及其用途 |
| WO2025019780A1 (en) * | 2023-07-20 | 2025-01-23 | Exelixis, Inc. | Activatable tyrosine-protein kinase membrane receptor (ror) antibody-drug conjugates and uses thereof |
| WO2025132812A1 (en) * | 2023-12-20 | 2025-06-26 | Antalgenics, S.L. | Phospholipase c inhibitor peptides and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| US9316646B2 (en) * | 2009-04-23 | 2016-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| WO2011079902A2 (en) | 2009-12-18 | 2011-07-07 | Biolnvent International Ab | Biological materials and uses thereof |
| WO2011159847A2 (en) * | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| WO2012045085A1 (en) | 2010-10-01 | 2012-04-05 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
| US9758586B2 (en) * | 2010-12-01 | 2017-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| KR102312856B1 (ko) * | 2012-08-24 | 2021-10-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| JP2017536341A (ja) | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
| CN107207592B (zh) * | 2014-12-05 | 2021-11-23 | 默克专利有限公司 | 结构域交换的抗体 |
| WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| TW202126682A (zh) | 2015-01-16 | 2021-07-16 | 美商奇諾治療有限公司 | 針對ror1之特異性抗體及嵌合抗原受體 |
| WO2016142768A1 (en) * | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
| HK1253507A1 (zh) | 2015-05-18 | 2019-06-21 | Eureka Therapeutics, Inc. | 抗 ror1 抗體 |
| MX2018003292A (es) | 2015-09-21 | 2018-08-01 | Aptevo Res & Development Llc | Polipéptidos de unión a cd3. |
| CN109311982A (zh) | 2016-01-20 | 2019-02-05 | 斯克利普斯研究所 | Ror2抗体组合物和相关方法 |
| TW201734049A (zh) * | 2016-01-22 | 2017-10-01 | 健生生物科技公司 | 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| NZ752832A (en) | 2016-10-19 | 2025-06-27 | Invenra Inc | Antibody constructs |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
-
2019
- 2019-04-18 US US17/048,549 patent/US12084496B2/en active Active
- 2019-04-18 CN CN201980040982.8A patent/CN112384533A/zh active Pending
- 2019-04-18 MY MYPI2020005435A patent/MY207121A/en unknown
- 2019-04-18 JP JP2020556851A patent/JP2021522162A/ja active Pending
- 2019-04-18 MX MX2020010881A patent/MX2020010881A/es unknown
- 2019-04-18 EP EP19789299.5A patent/EP3797122A4/en active Pending
- 2019-04-18 WO PCT/US2019/028051 patent/WO2019204564A1/en not_active Application Discontinuation
- 2019-04-18 EA EA202092202A patent/EA202092202A1/ru unknown
- 2019-04-18 KR KR1020207032901A patent/KR20200143470A/ko active Pending
- 2019-04-18 BR BR112020021269-5A patent/BR112020021269A2/pt unknown
- 2019-04-18 IL IL316574A patent/IL316574A/en unknown
- 2019-04-18 SG SG11202010235QA patent/SG11202010235QA/en unknown
- 2019-04-18 AU AU2019256431A patent/AU2019256431A1/en active Pending
- 2019-04-18 CA CA3097704A patent/CA3097704A1/en active Pending
-
2020
- 2020-10-14 MX MX2025001900A patent/MX2025001900A/es unknown
- 2020-10-14 MX MX2025001902A patent/MX2025001902A/es unknown
- 2020-10-14 IL IL278061A patent/IL278061A/en unknown
- 2020-10-14 MX MX2025001906A patent/MX2025001906A/es unknown
- 2020-10-16 PH PH12020551716A patent/PH12020551716A1/en unknown
-
2023
- 2023-10-04 JP JP2023172867A patent/JP2023168551A/ja not_active Withdrawn
-
2024
- 2024-08-12 US US18/801,013 patent/US20240392002A1/en active Pending